Brazil · Delayed Price · Currency is BRL CM Hospitalar S/A Earnings Call Transcripts
Fiscal Year 2026
-
Q1 saw modest revenue growth but strong margin and EBITDA improvements, driven by a selective commercial strategy and operational discipline. Cash generation was positive despite seasonal challenges, leverage declined, and the competitive environment supported margin gains in key segments.
Fiscal Year 2025
-
Operational discipline and selective contract strategy led to resumed growth and margin expansion in Q4 2025. Record cash generation and improved leverage position the company for continued efficiency and profitability focus in 2026.
-
Operational turnaround led to improved gross and EBITDA margins, robust cash generation, and reduced leverage. Strategic focus on efficiency, pricing, and working capital is driving sustainable profitability, with further gains expected in 2026.
-
Q2 2025 saw 2.5% revenue growth and 6.8% gross profit increase, with margin expansion driven by contract renegotiations and strong retail and vaccine performance. Leverage improved to 4.33x, and cash generation remains a key focus for H2.
-
Gross margin reached a five-quarter high at 13.8% and expenses fell nearly 6% year-over-year, with stable adjusted EBITDA despite lower revenues. Contract renegotiations and plant consolidation are expected to drive further improvements, while all business segments are projected to grow in 2025.
Fiscal Year 2024
-
Operational integration and efficiency took priority in 2024, with a shift from rapid growth to margin and cash flow recovery. Non-recurring write-downs impacted results, but cash flow turned positive and margin recovery is expected in 2025.
-
Q3 2024 saw operational stabilization, strong cash generation, and improved working capital, despite lower year-over-year margins due to mix effects and one-off provisions. Integration and cost initiatives are expected to drive further margin recovery and efficiency gains in 2025.
-
Operational improvements and cost reductions drove strong cash generation and lower leverage, despite a small adjusted net loss in Q2. Inventory and working capital optimization remain priorities, with further margin and profitability gains expected from Q4 2024 onward.